Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arcutis Biotherapeutics Inc 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361 USA

www.arcutis.com P: 805-418-5006

Description:

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.

Key Statistics

Overview:

Market Capitalization, $K 847,114
Enterprise Value, $K 959,594
Shares Outstanding, K 96,813
Annual Sales, $ 59,610 K
Annual Net Income, $ -262,140 K
Last Quarter Sales, $ 13,530 K
Last Quarter Net Income, $ -66,280 K
EBIT, $ -241,100 K
EBITDA, $ -246,570 K
60-Month Beta 1.14
% of Insider Shareholders 20.70%
Float, K 76,773
% Float 79.30%
Short Volume Ratio 0.47

Growth:

1-Year Return -35.75%
3-Year Return -74.36%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.72 on 02/27/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -3.92
EPS Growth vs. Prev Qtr 1.37%
EPS Growth vs. Prev Year 38.98%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ARQT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -294.85%
Return-on-Assets % -78.57%
Profit Margin % -439.76%
Debt/Equity 2.28
Price/Sales 14.20
Price/Cash Flow N/A
Price/Book 9.52
Book Value/Share 0.94
Interest Coverage -7.72
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar